Omalizumab for Food Allergy

This trial examines how quickly omalizumab, a treatment for food allergies, begins to work. Researchers aim to determine if it reduces allergy symptoms within 2 to 4 weeks of starting the treatment. Participants will undergo food challenges and tests before and after beginning omalizumab to monitor changes. This trial may suit individuals aged 1 to 30 with a diagnosed food allergy to specific foods like milk, egg, or peanuts, who have been prescribed omalizumab by their doctor. As a Phase 4 trial, this research seeks to understand how this FDA-approved and effective treatment benefits more patients.

You may need to stop taking certain medications, like antihistamines, for a short time before specific tests. If you're currently on corticosteroids, tricyclic antidepressants, or β-blockers, you cannot participate in the trial.

A previous study tested omalizumab for safety in people with allergies and found it to be well-tolerated, meaning most participants did not experience problems. The FDA has already approved omalizumab for treating food allergies in individuals aged 1 year and older, indicating its general safety. Other studies have reported mild side effects, such as headaches and injection site reactions like redness or swelling. Serious side effects are rare. Overall, omalizumab appears to be a safe option for people with food allergies.¹²³⁴⁵

Omalizumab is unique because it offers a targeted approach by blocking immunoglobulin E (IgE), a key player in the allergic response. Unlike many standard treatments for food allergies that aim to manage symptoms after they occur, omalizumab works by preventing allergic reactions from happening in the first place. This is particularly exciting for researchers because it could mean fewer allergic reactions and potentially less anxiety for patients with food allergies. Additionally, omalizumab is administered via subcutaneous injection, which can be tailored in dosage and frequency, offering a flexible option for patients and doctors.

Research has shown that omalizumab can significantly benefit people with food allergies by increasing the amount of food needed to trigger an allergic reaction. For example, it helps individuals tolerate more peanuts, milk, eggs, and cashews. In one study, 36% of participants could consume at least 2,000 mg of peanut protein after treatment, equivalent to about eight peanuts. Omalizumab also improves the overall quality of life for those with food allergies by reducing anxiety and boosting confidence in managing food exposure. While not a cure, it provides extra protection against accidental allergen contact. Participants in this trial will receive omalizumab as part of their routine care for food allergies, as prescribed by their doctor in the clinical setting.⁶⁷⁸⁹¹⁰